New S-1 Filing: RSU & Capital Gains Tax Exposure Calculator (Oct 9, 2026)

What Changed

Retention Pharmaceuticals filed an S-1MEF on October 8, 2026, a registration statement tied to a follow-on or concurrent offering alongside its primary IPO filing. The filing size runs 207 KB, consistent with a supplemental prospectus rather than a full initial registration. This signals the company is finalizing share allocation mechanics ahead of pricing, typically a 5 to 15 day window before trading begins.

The Numbers That Matter

Filing Stage	Typical Timeline	Share Price Volatility	Lockup Period
S-1 Initial Filing	Day 0	Not applicable	Not applicable
S-1MEF (Supplemental)	Day 20 to 45	Plus or minus 8% pre-pricing	Not yet triggered
Pricing Date	Day 30 to 60	Plus or minus 15% day one	90 to 180 days post-IPO
Lockup Expiration	Day 180 to 270	Minus 12% to minus 20% average drop	Event concludes

Pharmaceutical IPOs priced in 2024 and 2025 averaged a 14% first-day gain and a 17% decline at lockup expiration, per Nasdaq IPO data. The MEF filing does not guarantee allocation access for retail-adjacent HNW investors.

What This Means for Your Portfolio

A $1M portfolio allocating a standard 2% speculative sleeve to a single biotech IPO puts $20,000 at risk with a realistic dispersion of outcomes between minus 40% and plus 60% in the first 12 months. For a $2M portfolio running the same 2% allocation discipline, that is $40,000 exposed to binary clinical trial or regulatory catalysts that most diversified holdings do not carry. Pre-revenue pharmaceutical names also carry elevated short-term capital gains exposure if sold inside 12 months, taxed at ordinary income rates up to 37% federal plus applicable state tax.

Scenario Analysis

Position Size	2% Allocation	Gain Scenario (plus 60%)	Loss Scenario (minus 40%, net of tax offset)
$500K portfolio	$10,000	$16,000 (pre-tax)	$6,000 remaining, $4,000 loss offsets ordinary income up to $3,000 per year
$1M portfolio	$20,000	$32,000 (pre-tax)	$12,000 remaining, $8,000 loss carries forward
$2M portfolio	$40,000	$64,000 (pre-tax)	$24,000 remaining, $16,000 loss carries forward

The holder's marginal rate determines the tax on short-term gains in the upside scenario. For a $1M position in the 37% federal bracket, the $32,000 gross gain reduces to approximately $20,160 net before state tax.

Frequently Asked Questions

Q: What does an S-1MEF filing mean versus a standard S-1? A: An S-1MEF is a Rule 462(b) filing that registers additional shares, typically filed within days of pricing to accommodate overallotment or upsized demand.

Q: Does this filing mean Retention Pharmaceuticals is about to start trading? A: Not immediately. MEF filings generally precede pricing by a few days to two weeks, not a fixed deadline.

Q: How should investors approach pre-IPO or day-one allocation? A: Many investors use a predefined speculative sleeve, typically 1% to 3% of total portfolio value, because the sector has averaged minus 17% declines at lockup expiration. Individual circumstances vary, and investors should consult a financial advisor.

Q: How is an IPO loss treated on a tax return if the position is sold within a year? A: Short-term losses offset ordinary income up to $3,000 per year, with any excess carried forward to future tax years under IRS rules.

Run the Numbers

This article is for informational purposes only and does not constitute professional financial advice. Consult a qualified financial advisor before making investment decisions.

Use CalcMoney's Calculate Your After-Tax RSU Proceeds to see your exact figures under the current tax threshold.

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.

Featured Partner

FIDELITY